

DAFTAR PUSTAKA

1. WHO(2015). Cancer: Breast Cancer. World Health Organization. <http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/> - Diakses September 2017.
2. American Cancer Society. Breast Cancer Facts and Figures 2017-2018. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf> - Diakses Desember 2017.
3. Komite Nasional Penanggulangan Kanker. Pedoman Nasional Pelayanan Kedokteran Kanker Payudara. Kementerian Kesehatan RI. <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf> - Diakses September 2017.
4. Kementerian Kesehatan RI. InfoDatin Bulan Peduli Kanker Payudara. Pusat Data dan Informasi Kementerian Kesehatan RI. <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf> - Diakses September 2017.
5. Holliday DL, Speirs V. Choosing The Right Cell Line For Breast Cancer Research. *BioMed Central*. 2011;13:1-5
6. Yersal O, Barutca S. Biological Subtypes of Breast Cancer: Prognostic and Therapeutic Implications. *World Journal of Clinical Oncology*. 2014;5(3):412–25.
7. Aman RA, Gondhowiardjo S, Rachman A, Sufiadireja A, Syahrudin E, Tobing DL, et al. Ilmu Dasar Onkologi. 3rd ed. Jakarta: FK UI; 2010. p. 36-65.
8. Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-rodriguez M, et al. MYC Functions Are Specific In Biological Subtypes Of Breast Cancer And Confers Resistance To Endocrine Therapy In Luminal Tumours. *BJC*. 2016;114(8):917–28.
9. Fallah Y, Brundage J, Allegakoen P, Shajahan-haq AN. MYC-Driven Pathways in Breast Cancer Subtypes. *Biomolecules*. 2017;1–6.
10. Clarke R, Tyson JJ, Dixon M. Endocrine Resistance in Breast Cancer. *Mol*

- Cell Endocrinol. 2015;418(3):220-34.
11. Comsa S, Cimpean AM, Raica M. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. *Anticancer Research*. 2015;3154:3147–54.
 12. Diessner J, Wischnewsky M, Blettner M, Hsusler S, Janni W, Kreienberg R, et al. Do Patients With Luminal A Breast Cancer Profit From Adjuvant Systemic Therapy? A Retrospective Multicenter Study. *PLoS One*. 2016;11(12):1–15.
 13. Halim D, Murti H, Sandra F, Boediman ATD, Setiawan BS. *Stem Cell Dasar Teori dan Aplikasi Klinis*. Jakarta: Erlangga; 2010. p. 4-125.
 14. Pham P V, Vu NB, Pham VM, Truong NH, Pham TL, Dang LT. Good Manufacturing Practice-Compliant Isolation And Culture Of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. *J Transl Med*. 2014;12(1):1–10.
 15. Snell Richards S. *Anatomi Klinis Berdasarkan Sistem*. Sugiarto L, editor. Jakarta: EGC; 2012. p. 87-92.
 16. Bickley Lynn S. *Bates Buku Ajar Pemeriksaan Fisik dan Riwayat Kesehatan*. 8th ed. Hartono A, editor. Jakarta: EGC; 2012. p. 303-306.
 17. Sjamsuhidajat R, De Jong W. *Buku Ajar Ilmu Bedah*. 2nd ed. Jakarta: EGC; 2005. p. 140-145.
 18. Mescher Anthony L. *Histologi Dasar Junqueira Teks dan Atlas*. 12th ed. Dany F, editor. Jakarta: EGC; 2012. p. 396-401.
 19. Kumar V, Cotran R, RS. *Robbins Buku Ajar Patologi Volume 1*. 7th ed. Prasetyo A, Brahm U, Pendit TP, editor. Jakarta: EGC; 2012. 765-770 p.
 20. Ramli M. Update Breast Cancer Management. *Kedokteran Andalas*. 2015;38:40.
 21. Vuong D. Molecular classification of breast cancer. *Virchows Arch*. 2014;465:1–14.
 22. Levenson a S, Jordan VC. MCF-7: The First Hormone-Responsive Breast Cancer Cell Line. *Cancer Res*. 1997;57(15):3071–8.
 23. Vantangoli MM, Madnick SJ, Huse SM, Weston P, Boekelheide K. MCF-7 Human Breast Cancer Cells Form Differentiated Microtissues In Scaffold-

- Free Hydrogels. PLoS One. 2015;10(8):1–20.
24. Wang Y, Liu S, Zhang G, Zhou C, Zhu H, Zhou X, et al. Knockdown Of C-Myc Expression By Rnai Inhibits MCF-7 Breast Tumor Cells Growth In Vitro and In Vivo. *Breast Cancer Res.* 2005;7(2):R220-8.
 25. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, et al. Estrogen Induces C -Myc Gene Expression Via An Upstream Enhancer Activated By The Estrogen Receptor And The AP-1 Transcription Factor. *Mol Endocrinol.* 2011;25(9):1527–38.
 26. Chi V. Dang. Myc on the Path to Cancer. NIH Public Access. 2013;149(1):22–35.
 27. Guyton, Arthur C, JhonE. *Buku Ajar Fisiologi Kedokteran.* 12th Ed. Jakarta:Saunders Elsevier. 2014. p. 1098-99.
 28. Pham PV, Nguyen ST, Phan NLC, Phan NK. Roles of CD44 in Stem Cells and Cancer Stem Cells. *ResearchGate.* 2010.
 29. Shen CJ, Chan TF, Chen CC, Hsu YC, Long CY, Lai CS. Human Umbilical Cord Matrix-Derived Stem Cells Expressing Interferon- β Gene Inhibit Breast Cancer Cells via Apoptosis. *Oncotarget.* 2015;7(23):34172-8.
 30. Jeong JA, Hong SH, Gang EJ, Ahn C, Hwang SH, Yang IH, et al. Differential Gene Expression Profiling of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells by DNA Microarray. *Stem Cells.* 2005;23:584-93.
 31. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. *American Association fo Cancer Research.* 2010;16:6100-10.
 32. Xu J, Chen Y, Olopade OI. Myc and Breast Cancer. *Gene and Cancers.* 2010;1(6):629-40.
 33. Balantaco J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of Amplification and Overexpression of the c-Myc Oncogene in High-grade Breast Cancer: FISH, in Situ Hybridisation, and Immunohistochemical Analyses. *British Journal of Cancer.* 2004;90(8):1612-19.
 34. Liu E, Santos G, Lee WMF, Osborne C. K, Benz C. Effects of c-myc

- overexpression on the growth characteristics of MCF-7 human breast cancer cells. *Oncogene*. 1989. 4979–984.
35. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. *Medical Science*. 1998;95:15665-15670.
 36. Rhodes LV, Antoon JW, Muir SE, Elliot S, Beckman BS, Burow ME. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. *Molecular Cancer*. 2010;9:295.
 37. Chen J, Crawford R, Chen C, Xiao Y. The Key Regulatory Roles of the PI3K/Akt Signaling Pathway in the Functionalities of Mesenchymal Stem Cells and Applications in Tissue Regeneration. *Tissue Engineering*. 2012;19(6):516-528.
 38. Adelipour M, Babaei F, Mirzababaei M, Allameh A. Correlation of micro vessel density and c-Myc expression in breast tumor of mice following mesenchymal stem cell therapy. *Tissue and Cell*. 2017;49(2):315-322.
 39. Wang W, Zhong W, Yuan J, et al. Involvement of Wnt/ β -catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. *Oncotarget*. 2015;6(39):42276-89.
 40. Wu Q, Jin C, Chen H, Li XY, Li YJ. Interaction of adipose-derived mesenchymal stem cells with MCF-7 cells in vitro: a study emphasizing signaling molecule expression and transcriptional changes. *Turkish Journal of Biology*. 2017;41:785-795.
 41. Patel SA, Heinrich AC, Reddy BY, Srinivas B, Heidarani N, Rameshwar P. Breast Cancer Biology: The Multifaceted Roles of Mesenchymal Stem Cells, *Journal of Oncology*. 2008;2008:1-7.
 42. Dzobo K, Vogelsang M, Thomford NE, et al. Wharton's Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer Cells In Vitro. *Stem Cell Internasional*. 2016;2016:4842134.
 43. Orr MS, Fornari FA, Randolph JK, Gewirtz DA. Transcriptional down-

regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26. *Biochimica et Biophysica Acta*. 1995;1262(2-3):139-145.

44. Ma Y, Hao X, Zhang S, Zhang J. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells. *Breast Cancer Res Treat*. 2012;133(2):473-485.
45. Chao KC, Yang HT, Chen WM. Human umbilical cord mesenchymal stem cells suppress breast cancer tumorigenesis through direct cell–cell contact and internalization. *Journal of Cellular and Molecular Medicine*. 2012;16(8):1803-1815.
46. Li T, Zhang C, Ding Y, et al. Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway. *Oncology Report*. 2015;34:1469-1477.

